VTGN has been in the news 643% more than usual
Jan 23, 2026, 1:32 AM
-15.39%
What does VTGN do
VistaGen Therapeutics, a biopharmaceutical company based in South San Francisco, develops treatments for anxiety and depression using intranasal pherines and other therapies targeting central nervous system disorders. The company’s pipeline includes five clinical-stage investigational agents and went public on October 18, 2010.
VTGN has been in the news recently: Vistagen Therapeutics investors are facing a class action lawsuit due to alleged securities fraud that resulted in an 80% decline in stock price, dropping from $4.36 to $0.86. Multiple law firms, including Levi & Korsinsky, LLP, The Gross Law Firm, and Rosen Law Firm, are urging shareholders who purchased shares between April 1, 2024, and December 16, 2025, to participate in the lawsuit.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.